Growth and aging: a common molecular mechanism.

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget (2011) 3.43

Target of rapamycin (TOR) in nutrient signaling and growth control. Genetics (2011) 3.28

Regulation of yeast chronological life span by TORC1 via adaptive mitochondrial ROS signaling. Cell Metab (2011) 3.13

mTOR complex 2 signaling and functions. Cell Cycle (2011) 2.66

Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging. Aging (Albany NY) (2012) 2.59

Cell size and growth rate are major determinants of replicative lifespan. Cell Cycle (2011) 2.26

Answering the ultimate question "what is the proximal cause of aging?". Aging (Albany NY) (2012) 2.04

DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence. Aging (Albany NY) (2010) 1.97

Hypoxia suppresses conversion from proliferative arrest to cellular senescence. Proc Natl Acad Sci U S A (2012) 1.83

Yeast-like chronological senescence in mammalian cells: phenomenon, mechanism and pharmacological suppression. Aging (Albany NY) (2011) 1.74

mTOR's role in ageing: protein synthesis or autophagy? Aging (Albany NY) (2009) 1.59

State of the science: an update on renal cell carcinoma. Mol Cancer Res (2012) 1.58

Macronutrient balance and lifespan. Aging (Albany NY) (2009) 1.57

Alternative Perspectives on Aging in Caenorhabditis elegans: Reactive Oxygen Species or Hyperfunction? Antioxid Redox Signal (2012) 1.53

Once again on rapamycin-induced insulin resistance and longevity: despite of or owing to. Aging (Albany NY) (2012) 1.41

Rapalogs in cancer prevention: anti-aging or anticancer? Cancer Biol Ther (2012) 1.40

Transcriptional regulation in yeast during diauxic shift and stationary phase. OMICS (2010) 1.38

Sulfur amino acids regulate translational capacity and metabolic homeostasis through modulation of tRNA thiolation. Cell (2013) 1.30

Molecular damage in cancer: an argument for mTOR-driven aging. Aging (Albany NY) (2011) 1.29

Weekly administration of rapamycin improves survival and biomarkers in obese male mice on high-fat diet. Aging Cell (2014) 1.27

Potential anti-aging agents suppress the level of constitutive mTOR- and DNA damage- signaling. Aging (Albany NY) (2012) 1.24

Dual mTORC1/C2 inhibitors suppress cellular geroconversion (a senescence program). Oncotarget (2015) 1.23

Is cancer a metabolic rebellion against host aging? In the quest for immortality, tumor cells try to save themselves by boosting mitochondrial metabolism. Cell Cycle (2012) 1.22

Rapamycin extends life- and health span because it slows aging. Aging (Albany NY) (2013) 1.19

Immunosuppressants in cancer prevention and therapy. Oncoimmunology (2013) 1.17

Molecular links between cellular senescence, longevity and age-related diseases - a systems biology perspective. Aging (Albany NY) (2011) 1.12

A new dominant peroxiredoxin allele identified by whole-genome re-sequencing of random mutagenized yeast causes oxidant-resistance and premature aging. Aging (Albany NY) (2010) 1.12

mTOR coordinates protein synthesis, mitochondrial activity and proliferation. Cell Cycle (2015) 1.11

Why human lifespan is rapidly increasing: solving "longevity riddle" with "revealed-slow-aging" hypothesis. Aging (Albany NY) (2010) 1.11

Hormesis does not make sense except in the light of TOR-driven aging. Aging (Albany NY) (2011) 1.10

Rapamycin increases oxidative stress response gene expression in adult stem cells. Aging (Albany NY) (2012) 1.08

Geroconversion: irreversible step to cellular senescence. Cell Cycle (2014) 1.07

Why men age faster but reproduce longer than women: mTOR and evolutionary perspectives. Aging (Albany NY) (2010) 1.07

Linking calorie restriction to longevity through sirtuins and autophagy: any role for TOR. Cell Death Dis (2010) 1.07

Progeria, rapamycin and normal aging: recent breakthrough. Aging (Albany NY) (2011) 1.06

Mechanistic or mammalian target of rapamycin (mTOR) may determine robustness in young male mice at the cost of accelerated aging. Aging (Albany NY) (2012) 1.05

TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists. Cell Death Dis (2013) 1.04

How to save Medicare: the anti-aging remedy. Aging (Albany NY) (2012) 1.04

Rapamycin reverses insulin resistance (IR) in high-glucose medium without causing IR in normoglycemic medium. Cell Death Dis (2014) 1.01

In search of antiaging modalities: evaluation of mTOR- and ROS/DNA damage-signaling by cytometry. Cytometry A (2014) 0.99

Berberine suppresses gero-conversion from cell cycle arrest to senescence. Aging (Albany NY) (2013) 0.98

Aging is not programmed: genetic pseudo-program is a shadow of developmental growth. Cell Cycle (2013) 0.98

Tumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion. Oncotarget (2014) 0.94

Koschei the immortal and anti-aging drugs. Cell Death Dis (2014) 0.93

Big mice die young but large animals live longer. Aging (Albany NY) (2013) 0.93

Lithocholic acid extends longevity of chronologically aging yeast only if added at certain critical periods of their lifespan. Cell Cycle (2012) 0.91

Living on the edge: stress and activation of stress responses promote lifespan extension. Aging (Albany NY) (2010) 0.90

Trichostatin A accentuates doxorubicin-induced hypertrophy in cardiac myocytes. Aging (Albany NY) (2010) 0.90

M(o)TOR of aging: MTOR as a universal molecular hypothalamus. Aging (Albany NY) (2013) 0.88

Inhibition of S6K by resveratrol: in search of the purpose. Aging (Albany NY) (2009) 0.88

Plants do not count… or do they? New perspectives on the universality of senescence. J Ecol (2013) 0.88

Xenohormetic, hormetic and cytostatic selective forces driving longevity at the ecosystemic level. Aging (Albany NY) (2010) 0.88

Death and dessert: nutrient signalling pathways and ageing. Curr Opin Cell Biol (2011) 0.87

2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling. Cell Metab (2015) 0.87

Comparison of rapamycin schedules in mice on high-fat diet. Cell Cycle (2014) 0.87

Sirtuins as regulators of the yeast metabolic network. Front Pharmacol (2012) 0.86

Fasting levels of hepatic p-S6 are increased in old mice. Cell Cycle (2014) 0.86

Beneficial effects of novel antagonists of GHRH in different models of Alzheimer's disease. Aging (Albany NY) (2012) 0.86

Why the disposable soma theory cannot explain why women live longer and why we age. Aging (Albany NY) (2010) 0.85

What is the Proximal Cause of Aging? Front Genet (2012) 0.85

Telomerase deficiency delays renal recovery in mice after ischemia-reperfusion injury by impairing autophagy. Kidney Int (2015) 0.84

Age-related neuroinflammation and changes in AKT-GSK-3β and WNT/ β-CATENIN signaling in rat hippocampus. Aging (Albany NY) (2015) 0.83

Rapamycin reverses the senescent phenotype and improves immunoregulation of mesenchymal stem cells from MRL/lpr mice and systemic lupus erythematosus patients through inhibition of the mTOR signaling pathway. Aging (Albany NY) (2016) 0.83

mTOR kinase inhibitor pp242 causes mitophagy terminated by apoptotic cell death in E1A-Ras transformed cells. Oncotarget (2015) 0.83

MTOR-driven quasi-programmed aging as a disposable soma theory: blind watchmaker vs. intelligent designer. Cell Cycle (2013) 0.82

Metformin and sex: Why suppression of aging may be harmful to young male mice. Aging (Albany NY) (2010) 0.82

Mechanisms underlying the anti-aging and anti-tumor effects of lithocholic bile acid. Int J Mol Sci (2014) 0.82

Recent progress in genetics of aging, senescence and longevity: focusing on cancer-related genes. Oncotarget (2012) 0.82

Potential therapeutic effects of the MTOR inhibitors for preventing ageing and progeria-related disorders. Br J Clin Pharmacol (2016) 0.82

Tissue-specific insulin signaling in the regulation of metabolism and aging. IUBMB Life (2014) 0.82

A structural basis for cellular senescence. Aging (Albany NY) (2009) 0.82

Energy excess is the main cause of accelerated aging of mammals. Oncotarget (2015) 0.81

Recent progress in targeting cancer. Aging (Albany NY) (2011) 0.80

Aging and the Mammalian regulatory triumvirate. Aging Dis (2010) 0.80

The Intricate Interplay between Mechanisms Underlying Aging and Cancer. Aging Dis (2014) 0.79

Interspecies Chemical Signals Released into the Environment May Create Xenohormetic, Hormetic and Cytostatic Selective Forces that Drive the Ecosystemic Evolution of Longevity Regulation Mechanisms. Dose Response (2011) 0.79

Aging and DNA damage in humans: a meta‐analysis study. Aging (Albany NY) (2014) 0.79

Building a new bridge between metabolism, free radicals and longevity. Aging (Albany NY) (2009) 0.79

A growing role for hypertrophy in senescence. FEMS Yeast Res (2012) 0.78

Chronological lifespan in stationary culture: from yeast to human cells. Aging (Albany NY) (2011) 0.78

Environmental signaling through the mechanistic target of rapamycin complex 1: mTORC1 goes nuclear. Cell Cycle (2014) 0.78

Aging causes decreased resistance to multiple stresses and a failure to activate specific stress response pathways. Aging (Albany NY) (2016) 0.77

Discovery of plant extracts that greatly delay yeast chronological aging and have different effects on longevity-defining cellular processes. Oncotarget (2016) 0.77

A novel approach to the discovery of anti-tumor pharmaceuticals: searching for activators of liponecrosis. Oncotarget (2016) 0.76

Six plant extracts delay yeast chronological aging through different signaling pathways. Oncotarget (2016) 0.76

Are there roles for brain cell senescence in aging and neurodegenerative disorders? Biogerontology (2014) 0.76

Quantitative proteomics of rat livers shows that unrestricted feeding is stressful for proteostasis with implications on life span. Aging (Albany NY) (2016) 0.76

Co-regulation of polar mRNA transport and lifespan in budding yeast Saccharomyces cerevisiae. Cell Cycle (2012) 0.75

microRNA-496 - A new, potentially aging-relevant regulator of mTOR. Cell Cycle (2016) 0.75

Rapid and simple detection of gero-suppressive agents. Oncotarget (2015) 0.75

Friend or foe: the dichotomous impact of T cells on neuro-de/re-generation during aging. Oncotarget (2016) 0.75

Gerosuppression by pan-mTOR inhibitors. Aging (Albany NY) (2016) 0.75

Molecular characterization and functional analysis of Cashmere goat mammalian target of rapamycin. DNA Cell Biol (2011) 0.75

From rapalogs to anti-aging formula. Oncotarget (2017) 0.75

Genes and quantitative genetic variation involved with senescence in cells, organs, and the whole plant. Front Genet (2015) 0.75

Inverse correlation between longevity and developmental rate among wild C. elegans strains. Aging (Albany NY) (2016) 0.75

Early and extraordinary peaks in physical performance come with a longevity cost. Aging (Albany NY) (2016) 0.75

Geroprotective and Radioprotective Activity of Quercetin, (-)-Epicatechin, and Ibuprofen in Drosophila melanogaster. Front Pharmacol (2016) 0.75

Phylogenetic ubiquity of the effects of altered ubiquinone biosynthesis on survival. Aging (Albany NY) (2011) 0.75

Chronological Lifespan in Yeast Is Dependent on the Accumulation of Storage Carbohydrates Mediated by Yak1, Mck1 and Rim15 Kinases. PLoS Genet (2016) 0.75

TOR signaling in growth and metabolism. Cell (2006) 35.29

AKT/PKB signaling: navigating downstream. Cell (2007) 31.26

THE LIMITED IN VITRO LIFETIME OF HUMAN DIPLOID CELL STRAINS. Exp Cell Res (1965) 21.61

daf-2, an insulin receptor-like gene that regulates longevity and diapause in Caenorhabditis elegans. Science (1997) 13.61

Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature (2004) 12.36

Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients. Science (2005) 11.31

Autophagy: from phenomenology to molecular understanding in less than a decade. Nat Rev Mol Cell Biol (2007) 10.79

Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. Curr Biol (2004) 9.96

The plasticity of aging: insights from long-lived mutants. Cell (2005) 9.88

The roles of intracellular protein-degradation pathways in neurodegeneration. Nature (2006) 9.77

Autophagy genes are essential for dauer development and life-span extension in C. elegans. Science (2003) 9.17

Extended longevity in mice lacking the insulin receptor in adipose tissue. Science (2003) 8.53

Calorie restriction extends Saccharomyces cerevisiae lifespan by increasing respiration. Nature (2002) 8.45

Genetic pathways that regulate ageing in model organisms. Nature (2000) 8.19

A mutant Drosophila insulin receptor homolog that extends life-span and impairs neuroendocrine function. Science (2001) 8.06

Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med (2005) 7.83

Genetics: influence of TOR kinase on lifespan in C. elegans. Nature (2003) 7.55

mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature (2007) 7.12

Extension of chronological life span in yeast by decreased TOR pathway signaling. Genes Dev (2006) 6.62

Calorie restriction--the SIR2 connection. Cell (2005) 6.51

Calorie restriction, SIRT1 and metabolism: understanding longevity. Nat Rev Mol Cell Biol (2005) 6.34

A nutrient sensor mechanism controls Drosophila growth. Cell (2003) 5.61

Regulation of cellular growth by the Drosophila target of rapamycin dTOR. Genes Dev (2000) 5.53

Lifespan extension by conditions that inhibit translation in Caenorhabditis elegans. Aging Cell (2007) 5.51

The TOR pathway interacts with the insulin signaling pathway to regulate C. elegans larval development, metabolism and life span. Development (2004) 5.27

Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy. Cell Metab (2008) 4.91

Reduced TOR signaling extends chronological life span via increased respiration and upregulation of mitochondrial gene expression. Cell Metab (2007) 4.59

Adipose-specific knockout of raptor results in lean mice with enhanced mitochondrial respiration. Cell Metab (2008) 4.36

The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity. J Biol Chem (2006) 4.28

Rapamycin decelerates cellular senescence. Cell Cycle (2009) 3.97

Inhibition of mRNA translation extends lifespan in Caenorhabditis elegans. Aging Cell (2007) 3.78

Yeast life span extension by depletion of 60s ribosomal subunits is mediated by Gcn4. Cell (2008) 3.58

Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet (2005) 3.45

Growth stimulation leads to cellular senescence when the cell cycle is blocked. Cell Cycle (2008) 3.37

MSN2 and MSN4 link calorie restriction and TOR to sirtuin-mediated lifespan extension in Saccharomyces cerevisiae. PLoS Biol (2007) 3.19

Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase. Oncogene (2006) 3.18

eIF4E function in somatic cells modulates ageing in Caenorhabditis elegans. Nature (2007) 3.07

Life span extension by calorie restriction depends on Rim15 and transcription factors downstream of Ras/PKA, Tor, and Sch9. PLoS Genet (2007) 3.07

Daughter cells of Saccharomyces cerevisiae from old mothers display a reduced life span. J Cell Biol (1994) 2.71

Mutations that increase the life span of C. elegans inhibit tumor growth. Science (2006) 2.48

Aging and immortality: quasi-programmed senescence and its pharmacologic inhibition. Cell Cycle (2006) 2.23

The Mammalian target of rapamycin pathway regulates nutrient-sensitive glucose uptake in man. Diabetes (2007) 2.09

Validation of anti-aging drugs by treating age-related diseases. Aging (Albany NY) (2009) 2.01

Defining cellular senescence in IMR-90 cells: a flow cytometric analysis. Proc Natl Acad Sci U S A (1988) 1.99

Activated FOXO-mediated insulin resistance is blocked by reduction of TOR activity. Cell Metab (2006) 1.99

Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation (2005) 1.94

TOR-mediated cell-cycle activation causes neurodegeneration in a Drosophila tauopathy model. Curr Biol (2006) 1.88

Extension of chronological life span by reduced TOR signaling requires down-regulation of Sch9p and involves increased mitochondrial OXPHOS complex density. Aging (Albany NY) (2009) 1.82

Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol (2006) 1.73

The disparity between human cell senescence in vitro and lifelong replication in vivo. Nat Biotechnol (2002) 1.69

Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. Am J Pathol (2003) 1.64

The role of cellular senescence in skin aging. J Investig Dermatol Symp Proc (1998) 1.46

Adult-onset growth hormone and insulin-like growth factor I deficiency reduces neoplastic disease, modifies age-related pathology, and increases life span. Endocrinology (2005) 1.45

Long-lived Klotho mice: new insights into the roles of IGF-1 and insulin in aging. Trends Endocrinol Metab (2006) 1.23

The thorny path linking cellular senescence to organismal aging. Mech Ageing Dev (2005) 1.22

Cell size regulation in mammalian cells. Cell Cycle (2007) 1.21

Effect of IGF-1 on the balance between autophagy of dysfunctional mitochondria and apoptosis. FEBS Lett (2004) 1.20

TOR signaling and S6 kinase 1: Yeast catches up. Cell Metab (2007) 1.13

Effect of mTOR inhibitor on body weight: from an experimental rat model to human transplant patients. Transpl Int (2008) 0.97

Proliferative potential of human fibroblasts: an inverse dependence on cell size. J Cell Physiol (1987) 0.95

Relationship between the replicative age and cell volume in Saccharomyces cerevisiae. Acta Biochim Pol (2006) 0.95

TOR and aging: less is more. Cell Metab (2007) 0.94

Review: to bud until death: the genetics of ageing in the yeast, Saccharomyces. Yeast (1996) 0.93

Hypothesis: cell volume limits cell divisions. Acta Biochim Pol (2006) 0.88

Individualization of immunosuppressive therapy. III. Sirolimus associated with a reduced incidence of malignancy. Transplant Proc (2006) 0.83

Conversion to everolimus in a patient with arterial hypertension and recurrent cutaneous neoplasia--a case report. Nephrol Dial Transplant (2006) 0.81

Pharmacokinetics of sirolimus in Thai healthy volunteers. J Med Assoc Thai (2005) 0.81

The relationship between cell size, the activity of DNA polymerase alpha and proliferative activity in human diploid fibroblast-like cell cultures. Exp Gerontol (1989) 0.80

Pharmacokinetics and metabolic disposition of sirolimus in healthy male volunteers after a single oral dose. Ther Drug Monit (2006) 0.79

TOR signaling in growth and metabolism. Cell (2006) 35.29

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol (2004) 12.12

Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell (2002) 11.59

Sch9 is a major target of TORC1 in Saccharomyces cerevisiae. Mol Cell (2007) 5.67

Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy. Cell Metab (2008) 4.91

Adipose-specific knockout of raptor results in lean mice with enhanced mitochondrial respiration. Cell Metab (2008) 4.36

TOR regulates ribosomal protein gene expression via PKA and the Forkhead transcription factor FHL1. Cell (2004) 4.21

Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov (2011) 4.05

Tor signalling in bugs, brain and brawn. Nat Rev Mol Cell Biol (2003) 3.97

Activation of mTORC2 by association with the ribosome. Cell (2011) 3.38

The expanding TOR signaling network. Curr Opin Cell Biol (2005) 3.30

Target of rapamycin (TOR) in nutrient signaling and growth control. Genetics (2011) 3.28

Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest (2011) 2.90

The TOR-controlled transcription activators GLN3, RTG1, and RTG3 are regulated in response to intracellular levels of glutamine. Proc Natl Acad Sci U S A (2002) 2.87

Glutaminolysis activates Rag-mTORC1 signaling. Mol Cell (2012) 2.82

mTOR signaling in disease. Curr Opin Cell Biol (2011) 2.73

mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest (2011) 2.72

Elucidating TOR signaling and rapamycin action: lessons from Saccharomyces cerevisiae. Microbiol Mol Biol Rev (2002) 2.69

mTOR in aging, metabolism, and cancer. Curr Opin Genet Dev (2013) 2.53

mTOR and the control of whole body metabolism. Curr Opin Cell Biol (2009) 2.52

Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis. Science (2013) 2.44

Tor2 directly phosphorylates the AGC kinase Ypk2 to regulate actin polarization. Mol Cell Biol (2005) 2.44

Activation of the RAS/cyclic AMP pathway suppresses a TOR deficiency in yeast. Mol Cell Biol (2004) 2.26

Molecular organization of target of rapamycin complex 2. J Biol Chem (2005) 2.15

Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant (2005) 2.09

PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis. PLoS One (2007) 2.07

TOR complex 2: a signaling pathway of its own. Trends Biochem Sci (2009) 2.05

mTOR complex 2 in adipose tissue negatively controls whole-body growth. Proc Natl Acad Sci U S A (2009) 2.05

Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c. Cell Metab (2012) 2.03

Where is mTOR and what is it doing there? J Cell Biol (2013) 1.91

Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease. Proc Natl Acad Sci U S A (2008) 1.65

Bidirectional crosstalk between endoplasmic reticulum stress and mTOR signaling. Trends Cell Biol (2012) 1.63

The TSC-mTOR pathway mediates translational activation of TOP mRNAs by insulin largely in a raptor- or rictor-independent manner. Mol Cell Biol (2008) 1.61

Genome-wide lethality screen identifies new PI4,5P2 effectors that regulate the actin cytoskeleton. EMBO J (2004) 1.59

The rapamycin-sensitive phosphoproteome reveals that TOR controls protein kinase A toward some but not all substrates. Mol Biol Cell (2010) 1.58

Cardiac raptor ablation impairs adaptive hypertrophy, alters metabolic gene expression, and causes heart failure in mice. Circulation (2011) 1.57

Yeast protein kinases and the RHO1 exchange factor TUS1 are novel components of the cell integrity pathway in yeast. Mol Cell Biol (2002) 1.53

The solution structure of the FATC domain of the protein kinase target of rapamycin suggests a role for redox-dependent structural and cellular stability. J Biol Chem (2005) 1.49

AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancer. Sci Signal (2011) 1.49

TOR1 and TOR2 have distinct locations in live cells. Eukaryot Cell (2008) 1.46

Feature Article: mTOR complex 2-Akt signaling at mitochondria-associated endoplasmic reticulum membranes (MAM) regulates mitochondrial physiology. Proc Natl Acad Sci U S A (2013) 1.42

mTORC2 critically regulates renal potassium handling. J Clin Invest (2016) 1.40

TOR signaling in invertebrates. Curr Opin Cell Biol (2009) 1.37

Hypoxia-induced endothelial proliferation requires both mTORC1 and mTORC2. Circ Res (2006) 1.31

Inhibition of mTORC1 by astrin and stress granules prevents apoptosis in cancer cells. Cell (2013) 1.25

Regulation of TOR by small GTPases. EMBO Rep (2012) 1.24

mTORC1 directly phosphorylates and regulates human MAF1. Mol Cell Biol (2010) 1.24

Mutual antagonism of target of rapamycin and calcineurin signaling. J Biol Chem (2006) 1.17

Quantitation of changes in protein phosphorylation: a simple method based on stable isotope labeling and mass spectrometry. Proc Natl Acad Sci U S A (2003) 1.17

Rank Difference Analysis of Microarrays (RDAM), a novel approach to statistical analysis of microarray expression profiling data. BMC Bioinformatics (2004) 1.16

Zim17, a novel zinc finger protein essential for protein import into mitochondria. J Biol Chem (2004) 1.13

SnapShot: mTOR signaling. Cell (2007) 1.12

TOR regulates late steps of ribosome maturation in the nucleoplasm via Nog1 in response to nutrients. EMBO J (2006) 1.10

NPR1 kinase and RSP5-BUL1/2 ubiquitin ligase control GLN3-dependent transcription in Saccharomyces cerevisiae. J Biol Chem (2004) 1.10

The RHO1-GAPs SAC7, BEM2 and BAG7 control distinct RHO1 functions in Saccharomyces cerevisiae. Mol Microbiol (2002) 1.05

TORC1-regulated protein kinase Npr1 phosphorylates Orm to stimulate complex sphingolipid synthesis. Mol Biol Cell (2013) 1.03

Third target of rapamycin complex negatively regulates development of quiescence in Trypanosoma brucei. Proc Natl Acad Sci U S A (2012) 1.03

Activated mTORC1 promotes long-term cone survival in retinitis pigmentosa mice. J Clin Invest (2015) 1.03

Regulation of ribosome biogenesis: where is TOR? Cell Metab (2006) 1.03

Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas. Blood (2013) 1.02

Calmodulin controls organization of the actin cytoskeleton via regulation of phosphatidylinositol (4,5)-bisphosphate synthesis in Saccharomyces cerevisiae. Biochem J (2002) 1.02

An amino acid shuffle activates mTORC1. Cell (2009) 1.01

mTORC2 Caught in a SINful Akt. Dev Cell (2006) 1.00

Brief report: the differential roles of mTORC1 and mTORC2 in mesenchymal stem cell differentiation. Stem Cells (2015) 0.97

Identification of the rapamycin-sensitive phosphorylation sites within the Ser/Thr-rich domain of the yeast Npr1 protein kinase. Rapid Commun Mass Spectrom (2008) 0.92

Inducible raptor and rictor knockout mouse embryonic fibroblasts. Methods Mol Biol (2012) 0.90

Glutaminolysis feeds mTORC1. Cell Cycle (2012) 0.89

Activating mutations in TOR are in similar structures as oncogenic mutations in PI3KCalpha. ACS Chem Biol (2009) 0.89

Impact papers on aging in 2009. Aging (Albany NY) (2010) 0.89

Rictor in perivascular adipose tissue controls vascular function by regulating inflammatory molecule expression. Arterioscler Thromb Vasc Biol (2013) 0.86

Negative regulation of phosphatidylinositol 4,5-bisphosphate levels by the INP51-associated proteins TAX4 and IRS4. J Biol Chem (2004) 0.85

Signal transduction: Linking nutrients to growth. Nature (2008) 0.84

Leucyl-tRNA synthetase: double duty in amino acid sensing. Cell Res (2012) 0.83

Target of rapamycin (TOR) kinase in Trypanosoma brucei: an extended family. Biochem Soc Trans (2013) 0.82

Holding back TOR advances mitosis. Nat Cell Biol (2007) 0.81

PAS kinase promotes cell survival and growth through activation of Rho1. Sci Signal (2012) 0.81

Selective ATP-competitive inhibitors of TOR suppress rapamycin-insensitive function of TORC2 in Saccharomyces cerevisiae. ACS Chem Biol (2012) 0.81

TSC on the peroxisome controls mTORC1. Nat Cell Biol (2013) 0.80

Ramping up mitosis: an AMPKα2-regulated signaling network promotes mitotic progression. Mol Cell (2012) 0.78

Conserved sequence motifs and the structure of the mTOR kinase domain. Biochem Soc Trans (2013) 0.78

Growth grows up: COCB themed issue on cell division, growth, and death. Curr Opin Cell Biol (2011) 0.76

An Amazing Turn of Events. Cell (2017) 0.75

An isogenic cell panel identifies compounds that inhibit proliferation of mTOR-pathway addicted cells by different mechanisms. J Biomol Screen (2013) 0.75